Pomalidomide-PEG3-C2-NH2

CAS No. 2093416-31-8

Pomalidomide-PEG3-C2-NH2( Cereblon Ligand-Linker Conjugates 5 | E3 ligase Ligand-Linker Conjugates 30 )

Catalog No. M26944 CAS No. 2093416-31-8

Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide based cereblon ligand and 3-unit PEG linker.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 393 Get Quote
10MG 590 Get Quote
25MG 1060 Get Quote
50MG 1591 Get Quote
100MG 2387 Get Quote
200MG 3580 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Pomalidomide-PEG3-C2-NH2
  • Note
    Research use only, not for human use.
  • Brief Description
    Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide based cereblon ligand and 3-unit PEG linker.
  • Description
    Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide based cereblon ligand and 3-unit PEG linker.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Cereblon Ligand-Linker Conjugates 5 | E3 ligase Ligand-Linker Conjugates 30
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    MRCK| ROCK1| ROCK2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2093416-31-8
  • Formula Weight
    448.476
  • Molecular Formula
    C21H28N4O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NCCOCCOCCOCCNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yen Ting Chen, et al. Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors. Med.Chem.Commun., 2011, 2, 73-75.
molnova catalog
related products
  • LY-3475070

    LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.

  • G280-9

    The G280-9 peptide, a common melanoma gp100 epitope restricted by MHC-associated HLA-A2. The G280-9 sequence is unique because it could be recognized by cytotoxic T lymphocytes at very low concentrations, however it shows low total immunogenicity that may be attributable to relatively low affinity of this peptide for the HLA-A2.

  • Tetrahydrodehydrodic...

    Tetrahydrodehydrodiconiferyl alcohol is a natural product.